Vyant Bio and OrganoTherapeutics are teaming up to speed the discovery of new candidates for treating Parkinson’s disease. The collaboration will leverage OrganoTherapeutic’s patient-derived “mini-brains” — midbrain organoids — derived from induced pluripotent stem cells (iPSCs) and Vyant Bio’s expertise in machine learning technology to identify new…
The first patient has been dosed in a Phase 3 trial testing GE Healthcare’s new dopamine transporter positron emission tomography (PET) tracer, which is designed to aid in the evaluation of adults with suspected parkinsonian syndromes, including Parkinson’s disease. The PET agent is a…
IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical trial assessing the potential of its umbilical cord-derived stem cell therapy for treating bradykinesia, an early motor symptom of Parkinson’s disease characterized by slowness or difficulty in movement. The open-label trial…
A positron emission tomography (PET) tracer for the alpha-synuclein protein, whose damaging clumps mark Parkinson’s, captured its toxic aggregates in a living brain for a first time — instead of in post-mortem tissue as is done to date, scientists reported. The tracer, called ACI-12589, is a diagnostic tool designed to…
JOGO-Gx, a device powered by an artificial intelligence-driven mobile app and wearable sensors, has shown early positive signs as a method to lessen motor symptoms in people with Parkinson’s disease. According to JOGO Health, the company that owns JOGO-Gx, using the device at least twice a week led…
Australian researchers have received a $1.37-million grant to assess the potential of an early diagnostic test for Parkinson’s disease. The test, developed by scientists at the UNSW Medicine & Health’s EMBL Australia Node in Single Molecule Science, is able to quantify the number of alpha-synuclein aggregates — a hallmark…
A $2.8 million National Institutes of Health (NIH) grant will fund research into the molecular mechanisms underlying multiple system atrophy (MSA), a progressive disorder driven by protein misfolding and clumping similar to Parkinson’s disease. Differences in the shape of the misfolded protein are being seen to distinguish the two neurodegenerative diseases,…
The Parkinson’s Foundation announced six winners of this year’s Nurse Faculty Award and Physical Therapy Faculty Award. Each winner receives up to $10,000 to support projects that might better the lives of those with Parkinson’s disease. The four physical therapists are graduates of the foundation’s Physical Therapy Faculty Program and the two…
Parkinson’s UK and Domainex are teaming up to develop small molecules aimed at lessening chronic brain inflammation and slowing the progression of Parkinson’s disease. “We are thrilled to have been selected by Parkinson’s UK to work on this promising project which has the potential to improve the…
A National Institutes of Health (NIH) grant worth $3.2 million will further research into how the rewiring of serotonin-producing nerve cells — a chemical messenger mostly involved in mood, cognition and memory — might help with controlling movement in people with advanced Parkinson’s disease. The grant, given to Christopher…
Get regular updates to your inbox.
